{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:53:05Z","timestamp":1791575585357,"version":"4.3.4"},"reference-count":187,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Following the discovery of nucleic acids by Friedrich Miescher in 1868, DNA and RNA were recognized as the genetic code containing the necessary information for proper cell functioning. In the years following these discoveries, vast knowledge of the seemingly endless roles of RNA have become better understood. Additionally, many new types of RNAs were discovered that seemed to have no coding properties (non-coding RNAs), such as microRNAs (miRNAs). The discovery of these new RNAs created a new avenue for treating various human diseases. However, RNA is relatively unstable and is degraded fairly rapidly once administered; this has led to the development of novel delivery mechanisms, such as nanoparticles to increase stability as well as to prevent off-target effects of these molecules. Current advances in RNA-based therapies have substantial promise in treating and preventing many human diseases and disorders through fixing the pathology instead of merely treating the symptomology similarly to traditional therapeutics. Although many RNA therapeutics have made it to clinical trials, only a few have been FDA approved thus far. Additionally, the results of clinical trials for RNA therapeutics have been ambivalent to date, with some studies demonstrating potent efficacy, whereas others have limited effectiveness and\/or toxicity. Momentum is building in the clinic for RNA therapeutics; future clinical care of human diseases will likely comprise promising RNA therapeutics. This review focuses on the current advances of RNA therapeutics and addresses current challenges with their development.<\/jats:p>","DOI":"10.3390\/ijms23052736","type":"journal-article","created":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T08:17:03Z","timestamp":1646122623000},"page":"2736","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":162,"title":["Current Advances in RNA Therapeutics for Human Diseases"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2413-157X","authenticated-orcid":false,"given":"Hannah","family":"Zogg","sequence":"first","affiliation":[{"name":"Department of Physiology and Cell Biology, Reno School of Medicine, University of Nevada, 1664 North Virginia Street, Reno, NV 89557, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5500-1949","authenticated-orcid":false,"given":"Rajan","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Physiology and Cell Biology, Reno School of Medicine, University of Nevada, 1664 North Virginia Street, Reno, NV 89557, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0861-8334","authenticated-orcid":false,"given":"Seungil","family":"Ro","sequence":"additional","affiliation":[{"name":"Department of Physiology and Cell Biology, Reno School of Medicine, University of Nevada, 1664 North Virginia Street, Reno, NV 89557, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41573-021-00219-z","article-title":"Noncoding RNA therapeutics\u2014Challenges and potential solutions","volume":"20","author":"Winkle","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"14385","DOI":"10.1073\/pnas.0405913101","article-title":"Biochemical identification of Argonaute 2 as the sole protein required for RNA-induced silencing complex activity","volume":"101","author":"Rand","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Singh, R., Zogg, H., and Ro, S. (2021). Role of microRNAs in Disorders of Gut-Brain Interactions: Clinical Insights and Therapeutic Alternatives. J. Pers. Med., 11.","DOI":"10.3390\/jpm11101021"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.cell.2005.08.044","article-title":"Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes","volume":"123","author":"Matranga","year":"2005","journal-title":"Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: Advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41392-020-00315-3","article-title":"Recent advances in the development of protein-protein interactions modulators: Mechanisms and clinical trials","volume":"5","author":"Lu","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-61779-921-1_1","article-title":"Therapeutic proteins","volume":"899","author":"Dimitrov","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.4155\/tde.13.104","article-title":"Basics and recent advances in peptide and protein drug delivery","volume":"4","author":"Bruno","year":"2013","journal-title":"Ther. Deliv."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Bajan, S., and Hutvagner, G. (2020). RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs. Cells, 9.","DOI":"10.3390\/cells9010137"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"785703","DOI":"10.3389\/fncel.2021.785703","article-title":"Innovative Therapeutic Approaches for Huntington\u2019s Disease: From Nucleic Acids to GPCR-Targeting Small Molecules","volume":"15","author":"Komatsu","year":"2021","journal-title":"Front. Cell Neurosci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3389\/fgene.2019.00478","article-title":"The Potential for microRNA Therapeutics and Clinical Research","volume":"10","author":"Hanna","year":"2019","journal-title":"Front. Genet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1053\/j.gastro.2020.12.062","article-title":"miR-10b-5p Rescues Diabetes and Gastrointestinal Dysmotility","volume":"160","author":"Singh","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_14","first-page":"467","article-title":"A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS","volume":"133","year":"2002","journal-title":"Am. J. Ophthalmol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jacl.2014.12.008","article-title":"Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia","volume":"9","author":"Santos","year":"2015","journal-title":"J. Clin. Lipidol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann. Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40478-020-01106-1","article-title":"The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy","volume":"9","author":"Scaglioni","year":"2021","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","article-title":"Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease","volume":"381","author":"Kim","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40265-021-01512-2","article-title":"Casimersen: First Approval","volume":"81","author":"Shirley","year":"2021","journal-title":"Drugs"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/mus.27347","article-title":"Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double-blind, placebo-controlled, dose-titration trial","volume":"64","author":"Wagner","year":"2021","journal-title":"Muscle Nerve"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","article-title":"Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial","volume":"77","author":"Clemens","year":"2020","journal-title":"JAMA Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria","volume":"382","author":"Balwani","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1681\/ASN.2016030338","article-title":"An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria","volume":"28","author":"Liebow","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40265-021-01473-6","article-title":"Inclisiran: First Approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.bbmt.2017.03.008","article-title":"Defibrotide for Patients with Hepatic Veno-Occlusive Disease\/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study","volume":"23","author":"Richardson","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e26463","DOI":"10.1097\/MD.0000000000026463","article-title":"Successful defibrotide treatment of a patient with veno-occlusive disease after living-donor liver transplantation: A case report","volume":"100","author":"Lee","year":"2021","journal-title":"Medicine"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2004-06-2156","article-title":"Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: Increased interferon-alpha\/beta-inducible gene expression, without significant toxicity","volume":"105","author":"Friedberg","year":"2005","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2141.2009.07773.x","article-title":"Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma","volume":"146","author":"Friedberg","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1093\/annonc\/mdw068","article-title":"A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers","volume":"27","author":"Chi","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/cncr.26292","article-title":"Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia","volume":"118","author":"Cortes","year":"2012","journal-title":"Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e122688","DOI":"10.1172\/jci.insight.122688","article-title":"Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy","volume":"4","author":"Kura","year":"2019","journal-title":"JCI Insight"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/JTO.0b013e31823f459c","article-title":"Phase I\/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer","volume":"7","author":"Laskin","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1093\/jnci\/dji252","article-title":"A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2\u2032-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer","volume":"97","author":"Chi","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_40","first-page":"747\u2013e218","article-title":"An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma","volume":"24","author":"Lim","year":"2019","journal-title":"Oncologist"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.cub.2006.12.037","article-title":"BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo","volume":"17","author":"Steegmaier","year":"2007","journal-title":"Curr. Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.1200\/JCO.2013.55.0376","article-title":"First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors","volume":"32","author":"Schultheis","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Schultheis, B., Strumberg, D., Kuhlmann, J., Wolf, M., Link, K., Seufferlein, T., Kaufmann, J., Feist, M., Gebhardt, F., and Khan, M. (2020). Safety, Efficacy and Pharcacokinetics of Targeted Therapy with The Liposomal RNA Interference Therapeutic Atu027 Combined with Gemcitabine in Patients with Pancreatic Adenocarcinoma. A Randomized Phase Ib\/IIa Study. Cancers, 12.","DOI":"10.3390\/cancers12113130"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"24560","DOI":"10.18632\/oncotarget.4183","article-title":"RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients","volume":"6","author":"Golan","year":"2015","journal-title":"Oncotarget"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"20723","DOI":"10.1073\/pnas.1314307110","article-title":"Mutant KRAS is a druggable target for pancreatic cancer","volume":"110","author":"Gabai","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1101\/sqb.2016.81.030833","article-title":"Targeting HIF2 in Clear Cell Renal Cell Carcinoma","volume":"81","author":"Cho","year":"2016","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/2051-1426-3-S2-P175","article-title":"Phase I clinical trial of adoptive cellular immunotherapy with APN401 in patients with solid tumors","volume":"3","author":"Triozzi","year":"2015","journal-title":"J. ImmunoTherapy Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cell.2005.01.018","article-title":"The biological and chemical basis for tissue-selective amyloid disease","volume":"121","author":"Sekijima","year":"2005","journal-title":"Cell"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/cpt.1974","article-title":"Single-Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N-acetylgalactosamine-Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects","volume":"109","author":"Habtemariam","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/14728214.2019.1604684","article-title":"Emerging PEGylated non-biologic drugs","volume":"24","author":"Park","year":"2019","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_51","first-page":"307","article-title":"C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria","volume":"32","author":"Menne","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1473-3099(21)00677-0","article-title":"Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): A randomised, observer-blinded, placebo-controlled, phase 2b\/3 trial","volume":"22","author":"Kremsner","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.omtm.2020.05.030","article-title":"Synthetic mRNA Encoding VEGF-A in Patients Undergoing Coronary Artery Bypass Grafting: Design of a Phase 2a Clinical Trial","volume":"18","author":"Anttila","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"R88","DOI":"10.1093\/hmg\/ddz139","article-title":"Advances in gene therapy for cystic fibrosis lung disease","volume":"28","author":"Yan","year":"2019","journal-title":"Hum. Mol. Genet"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1089\/hum.2019.113","article-title":"Gene Therapy for Methylmalonic Acidemia: Past, Present, and Future","volume":"30","author":"Chandler","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1016\/j.celrep.2017.11.081","article-title":"Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia","volume":"21","author":"An","year":"2017","journal-title":"Cell Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa1209026","article-title":"Treatment of HCV infection by targeting microRNA","volume":"368","author":"Janssen","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1172\/JCI75852","article-title":"Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways","volume":"125","author":"Gomez","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_60","first-page":"207","article-title":"Prognostic Value of miRNA-155 Expression in B-Cell Non-Hodgkin Lymphoma","volume":"34","author":"Bedewy","year":"2017","journal-title":"Turk. J. Haematol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1126\/science.1174381","article-title":"MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice","volume":"324","author":"Bonauer","year":"2009","journal-title":"Science"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nature10112","article-title":"MicroRNAs 103 and 107 regulate insulin sensitivity","volume":"474","author":"Trajkovski","year":"2011","journal-title":"Nature"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1038\/s41467-019-11918-y","article-title":"Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease","volume":"10","author":"Lee","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/eurheartj\/ehaa898","article-title":"Novel antisense therapy targeting microRNA-132 in patients with heart failure: Results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study","volume":"42","author":"Taubel","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S1470-2045(17)30621-6","article-title":"Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: A first-in-man, phase 1, open-label, dose-escalation study","volume":"18","author":"Pavlakis","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1165\/rcmb.2010-0323OC","article-title":"miR-29 is a major regulator of genes associated with pulmonary fibrosis","volume":"45","author":"Cushing","year":"2011","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10637-016-0407-y","article-title":"Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors","volume":"35","author":"Beg","year":"2017","journal-title":"Investig. New Drugs"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"REVIEWS0004","DOI":"10.1186\/gb-2002-3-3-reviews0004","article-title":"Untranslated regions of mRNAs","volume":"3","author":"Mignone","year":"2002","journal-title":"Genome Biol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/nrm.2017.103","article-title":"Functional 5\u2032 UTR mRNA structures in eukaryotic translation regulation and how to find them","volume":"19","author":"Leppek","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1089\/hum.2020.137","article-title":"Treating Cystic Fibrosis with mRNA and CRISPR","volume":"31","author":"Paunovska","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","article-title":"In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates","volume":"593","author":"Musunuru","year":"2021","journal-title":"Nature"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1126\/science.1546298","article-title":"Reversal of diabetes insipidus in Brattleboro rats: Intrahypothalamic injection of vasopressin mRNA","volume":"255","author":"Jirikowski","year":"1992","journal-title":"Science"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/eji.1830230749","article-title":"Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA","volume":"23","author":"Martinon","year":"1993","journal-title":"Eur. J. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.vaccine.2020.12.070","article-title":"Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial","volume":"39","author":"Aldrich","year":"2021","journal-title":"Vaccine"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/nbt.2436","article-title":"Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection","volume":"30","author":"Petsch","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1080\/21645515.2020.1829899","article-title":"A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults","volume":"17","author":"Aliprantis","year":"2021","journal-title":"Hum. Vaccin Immunother."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e0004746","DOI":"10.1371\/journal.pntd.0004746","article-title":"An mRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn Pigs","volume":"10","author":"Schnee","year":"2016","journal-title":"PLoS Negl. Trop. Dis."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Medina-Magues, L.G., Gergen, J., Jasny, E., Petsch, B., Lopera-Madrid, J., Medina-Magues, E.S., Salas-Quinchucua, C., and Osorio, J.E. (2021). mRNA Vaccine Protects against Zika Virus. Vaccines, 9.","DOI":"10.3390\/vaccines9121464"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.vaccine.2018.01.029","article-title":"Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity","volume":"36","author":"John","year":"2018","journal-title":"Vaccine"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"5358","DOI":"10.1016\/j.vaccine.2021.08.011","article-title":"Pre-existing immunity to cytomegalovirus in macaques influences human CMV vaccine responses in preclinical models","volume":"39","author":"Webster","year":"2021","journal-title":"Vaccine"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jss.2004.06.010","article-title":"HIV-based vectors and angiogenesis following rabbit hindlimb ischemia","volume":"123","author":"Conklin","year":"2005","journal-title":"J. Surg. Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/gt.2012.17","article-title":"VEGF gene therapy: Therapeutic angiogenesis in the clinic and beyond","volume":"19","author":"Giacca","year":"2012","journal-title":"Gene Ther."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/sj.bjp.0707315","article-title":"Cardiovascular gene therapy: Current status and therapeutic potential","volume":"152","author":"Gaffney","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Butnariu, L.I., Tarca, E., Cojocaru, E., Rusu, C., Moisa, S.M., Leon Constantin, M.M., Gorduza, E.V., and Trandafir, L.M. (2021). Genetic Modifying Factors of Cystic Fibrosis Phenotype: A Challenge for Modern Medicine. J. Clin. Med., 10.","DOI":"10.3390\/jcm10245821"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/MOP.0000000000000422","article-title":"Methylmalonic and propionic acidemias: Clinical management update","volume":"28","author":"Fraser","year":"2016","journal-title":"Curr. Opin. Pediatr."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"8247935","DOI":"10.1155\/2018\/8247935","article-title":"SERPINA1 mRNA as a Treatment for Alpha-1 Antitrypsin Deficiency","volume":"2018","author":"Connolly","year":"2018","journal-title":"J. Nucleic Acids"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.ymthe.2019.04.017","article-title":"mRNA Therapy Improves Metabolic and Behavioral Abnormalities in a Murine Model of Citrin Deficiency","volume":"27","author":"Cao","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"6174","DOI":"10.1158\/1078-0432.CCR-21-0987","article-title":"Spatial Mapping and Immunomodulatory Role of the OX40\/OX40L Pathway in Human Non-Small Cell Lung Cancer","volume":"27","author":"Porciuncula","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1158\/1078-0432.CCR-20-0472","article-title":"Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment","volume":"26","author":"Hewitt","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ajhg.2019.02.003","article-title":"Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human Primates","volume":"104","author":"Zhu","year":"2019","journal-title":"Am. J. Hum. Genet"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.addr.2015.03.008","article-title":"Antisense oligonucleotides in therapy for neurodegenerative disorders","volume":"87","author":"Evers","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1073\/pnas.75.1.285","article-title":"Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide","volume":"75","author":"Stephenson","year":"1978","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"17181","DOI":"10.1074\/jbc.M311683200","article-title":"Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs","volume":"279","author":"Wu","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.cell.2017.06.028","article-title":"Splicing-Correcting Therapy for SMA","volume":"170","author":"Wan","year":"2017","journal-title":"Cell"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1038\/s41467-020-17093-9","article-title":"Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression","volume":"11","author":"Lim","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1093\/nar\/gku184","article-title":"Nonsense-mediated decay as a terminating mechanism for antisense oligonucleotides","volume":"42","author":"Ward","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/nar\/19.5.1113","article-title":"Inhibition of translation initiation by antisense oligonucleotides via an RNase-H independent mechanism","volume":"19","author":"Boiziau","year":"1991","journal-title":"Nucleic Acids Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nbt.3589","article-title":"Translation efficiency of mRNAs is increased by antisense oligonucleotides targeting upstream open reading frames","volume":"34","author":"Liang","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/nar\/29.6.1293","article-title":"Fully modified 2\u2032 MOE oligonucleotides redirect polyadenylation","volume":"29","author":"Vickers","year":"2001","journal-title":"Nucleic Acids Res."},{"key":"ref_102","first-page":"84","article-title":"Fomiversen sodium approved to treat CMV retinitis","volume":"39","author":"Piascik","year":"1999","journal-title":"J. Am. Pharm. Assoc."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0002-9394(02)01325-9","article-title":"Fomivirsen for the treatment of cytomegalovirus retinitis","volume":"133","author":"Jabs","year":"2002","journal-title":"Am. J. Ophthalmol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3909\/ricm0834","article-title":"Balancing Low-density Lipoprotein Cholesterol Reduction and Hepatotoxicity With Lomitapide Mesylate and Mipomersen in Patients With Homozygous Familial Hypercholesterolemia","volume":"18","author":"Won","year":"2017","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.hfc.2021.07.008","article-title":"New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia","volume":"18","author":"Cesaro","year":"2022","journal-title":"Heart Fail Clin."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.atherosclerosissup.2015.02.005","article-title":"Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia","volume":"18","author":"Berthold","year":"2015","journal-title":"Atheroscler. Suppl."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/nat.2017.0665","article-title":"FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides","volume":"27","year":"2017","journal-title":"Nucleic Acid. Ther."},{"key":"ref_108","unstructured":"Burr, P., and Reddivari, A.K.R. (2022). Spinal Muscle Atrophy, StatPearls."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/nat.2016.0657","article-title":"FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga","volume":"27","author":"Krieg","year":"2017","journal-title":"Nucleic Acid Ther."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.ymthe.2017.02.019","article-title":"Progress toward Gene Therapy for Duchenne Muscular Dystrophy","volume":"25","author":"Chamberlain","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"9456","DOI":"10.1073\/pnas.142302299","article-title":"Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Delta 48-50 DMD cells","volume":"99","author":"Sthandier","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_112","unstructured":"Adam, M.P., Ardinger, H.H., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Gripp, K.W., Mirzaa, G.M., and Amemiya, A. (1993). Hereditary Transthyretin Amyloidosis, GeneReviews."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-1-0716-0771-8_6","article-title":"Inotersen for the Treatment of Hereditary Transthyretin Amyloidosis","volume":"2176","author":"Mahfouz","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"107719","DOI":"10.1016\/j.pharmthera.2020.107719","article-title":"Current and emerging therapies for Duchenne muscular dystrophy and spinal muscular atrophy","volume":"220","author":"Iftikhar","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.conb.2021.08.003","article-title":"On the cusp of cures: Breakthroughs in Batten disease research","volume":"72","author":"Brudvig","year":"2021","journal-title":"Curr. Opin. Neurobiol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00277-021-04729-z","article-title":"Non-Hodgkin lymphomas and ionizing radiation: Case report and review of the literature","volume":"101","author":"Wolff","year":"2022","journal-title":"Ann. Hematol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/7403","article-title":"Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo","volume":"5","author":"Fernandez","year":"1999","journal-title":"Nat. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/32588","article-title":"Dendritic cells and the control of immunity","volume":"392","author":"Banchereau","year":"1998","journal-title":"Nature"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1158\/1078-0432.CCR-14-1108","article-title":"Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth","volume":"21","author":"Yamamoto","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/cgt.2016.4","article-title":"Precise and efficient siRNA design: A key point in competent gene silencing","volume":"23","author":"Fakhr","year":"2016","journal-title":"Cancer Gene Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1042\/BCJ20160759","article-title":"Molecular mechanisms of Dicer: Endonuclease and enzymatic activity","volume":"474","author":"Song","year":"2017","journal-title":"Biochem. J."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.molcel.2021.11.026","article-title":"Life of RISC: Formation, action, and degradation of RNA-induced silencing complex","volume":"82","author":"Iwakawa","year":"2022","journal-title":"Mol. Cell"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1515\/hsz-2017-0329","article-title":"The AGO proteins: An overview","volume":"399","author":"Niaz","year":"2018","journal-title":"Biol. Chem."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s40265-018-0983-6","article-title":"Patisiran: First Global Approval","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1055\/s-0039-1688994","article-title":"Neuropathy Associated with Systemic Amyloidosis","volume":"39","author":"Kaku","year":"2019","journal-title":"Semin Neurol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40291-019-00438-6","article-title":"Leading RNA Interference Therapeutics Part 2: Silencing Delta-Aminolevulinic Acid Synthase 1, with a Focus on Givosiran","volume":"24","year":"2020","journal-title":"Mol. Diagn. Ther."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s40265-021-01511-3","article-title":"Givosiran: A Review in Acute Hepatic Porphyria","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40265-020-01463-0","article-title":"Lumasiran: First Approval","volume":"81","author":"Scott","year":"2021","journal-title":"Drugs"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.semcancer.2010.09.002","article-title":"Gene signatures in hepatocellular carcinoma (HCC)","volume":"21","author":"Andrisani","year":"2011","journal-title":"Semin. Cancer Biol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41575-019-0245-4","article-title":"Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer","volume":"17","author":"Buscail","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1038\/s41388-020-1234-3","article-title":"Modeling clear cell renal cell carcinoma and therapeutic implications","volume":"39","author":"Wolf","year":"2020","journal-title":"Oncogene"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"5435","DOI":"10.1038\/sj.onc.1203938","article-title":"Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function","volume":"19","author":"Krieg","year":"2000","journal-title":"Oncogene"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/35003228","article-title":"Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b","volume":"403","author":"Bachmaier","year":"2000","journal-title":"Nature"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/nature12998","article-title":"The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells","volume":"507","author":"Paolino","year":"2014","journal-title":"Nature"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0092-8674(93)90529-Y","article-title":"The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14","volume":"75","author":"Lee","year":"1993","journal-title":"Cell"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/0092-8674(93)90530-4","article-title":"Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans","volume":"75","author":"Wightman","year":"1993","journal-title":"Cell"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/nsmb.2296","article-title":"The mechanics of miRNA-mediated gene silencing: A look under the hood of miRISC","volume":"19","author":"Fabian","year":"2012","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1126\/science.1258040","article-title":"Structural basis for microRNA targeting","volume":"346","author":"Schirle","year":"2014","journal-title":"Science"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nrg3965","article-title":"Towards a molecular understanding of microRNA-mediated gene silencing","volume":"16","author":"Jonas","year":"2015","journal-title":"Nat. Rev. Genet"},{"key":"ref_140","first-page":"JVI-01903","article-title":"miR-122 affects both the initiation and maintenance of Hepatitis C Virus infections","volume":"96","author":"Panigrahi","year":"2021","journal-title":"J. Virol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1053\/j.ajkd.2020.03.026","article-title":"Alport Syndrome: Achieving Early Diagnosis and Treatment","volume":"77","author":"Kashtan","year":"2021","journal-title":"Am. J. Kidney Dis."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/carcin\/bgz183","article-title":"miR-155 as a novel clinical target for hematological malignancies","volume":"41","author":"Witten","year":"2020","journal-title":"Carcinogenesis"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/bjh.15547","article-title":"Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma","volume":"183","author":"Seto","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1158\/1078-0432.CCR-20-3139","article-title":"Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth In Vitro and In Vivo","volume":"27","author":"Anastasiadou","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1089\/nat.2020.0871","article-title":"Efficiency and Target Derepression of Anti-miR-92a: Results of a First in Human Study","volume":"30","author":"Abplanalp","year":"2020","journal-title":"Nucleic Acid Ther."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/wrr.12660","article-title":"A synthetic microRNA-92a inhibitor (MRG-110) accelerates angiogenesis and wound healing in diabetic and nondiabetic wounds","volume":"26","author":"Piper","year":"2018","journal-title":"Wound Repair Regen."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nrm3313","article-title":"MicroRNAs in metabolism and metabolic disorders","volume":"13","author":"Rottiers","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-981-10-2041-4_2","article-title":"Genetic Mechanisms of ADPKD","volume":"933","author":"Kim","year":"2016","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/ncomms2090","article-title":"The miRNA-212\/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy","volume":"3","author":"Ucar","year":"2012","journal-title":"Nat. Commun."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41467-020-14349-2","article-title":"Preclinical development of a miR-132 inhibitor for heart failure treatment","volume":"11","author":"Foinquinos","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/eurheartj\/ehaa791","article-title":"CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure","volume":"42","author":"Batkai","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"15524","DOI":"10.1073\/pnas.242606799","article-title":"Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia","volume":"99","author":"Calin","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"5553","DOI":"10.1158\/0008-5472.CAN-08-4277","article-title":"miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer","volume":"69","author":"Bandi","year":"2009","journal-title":"Cancer Res."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/nm.1880","article-title":"The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities","volume":"14","author":"Bonci","year":"2008","journal-title":"Nat. Med."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/annonc\/mdt412","article-title":"Restoring expression of miR-16: A novel approach to therapy for malignant pleural mesothelioma","volume":"24","author":"Reid","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/1878-0261.12588","article-title":"miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma","volume":"14","author":"Chava","year":"2020","journal-title":"Mol. Oncol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"e408","DOI":"10.5435\/JAAOS-D-19-00690","article-title":"Keloid and Hypertrophic Scar Formation, Prevention, and Management: Standard Review of Abnormal Scarring in Orthopaedic Surgery","volume":"28","author":"Grabowski","year":"2020","journal-title":"J. Am. Acad. Orthop. Surg."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/MAJ.0b013e318267680d","article-title":"Identification of collagen 1 as a post-transcriptional target of miR-29b in skin fibroblasts: Therapeutic implication for scar reduction","volume":"346","author":"Cheng","year":"2013","journal-title":"Am. J. Med. Sci."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.trsl.2016.07.001","article-title":"Overexpression of miR-29b reduces collagen biosynthesis by inhibiting heat shock protein 47 during skin wound healing","volume":"178","author":"Zhu","year":"2016","journal-title":"Transl. Res."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.15252\/emmm.201303604","article-title":"MicroRNA mimicry blocks pulmonary fibrosis","volume":"6","author":"Montgomery","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jid.2018.11.007","article-title":"A MicroRNA-29 Mimic (Remlarsen) Represses Extracellular Matrix Expression and Fibroplasia in the Skin","volume":"139","author":"Piper","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nm.2284","article-title":"The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44","volume":"17","author":"Liu","year":"2011","journal-title":"Nat. Med."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1158\/0008-5472.CAN-16-2183","article-title":"miR-34a and miR-34b\/c Suppress Intestinal Tumorigenesis","volume":"77","author":"Jiang","year":"2017","journal-title":"Cancer Res."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"e6816","DOI":"10.1371\/journal.pone.0006816","article-title":"MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells","volume":"4","author":"Ji","year":"2009","journal-title":"PLoS ONE"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"111967","DOI":"10.1016\/j.biopha.2021.111967","article-title":"Distinct roles of miR-34 family members on suppression of lung squamous cell carcinoma","volume":"142","author":"Sun","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12885-016-2135-2","article-title":"Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer","volume":"16","author":"Schmid","year":"2016","journal-title":"BMC Cancer"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.3892\/mmr.2017.6187","article-title":"miR-34a is downregulated in human osteosarcoma stem-like cells and promotes invasion, tumorigenic ability and self-renewal capacity","volume":"15","author":"Zou","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.molcel.2007.05.017","article-title":"Transcriptional activation of miR-34a contributes to p53-mediated apoptosis","volume":"26","author":"Marciano","year":"2007","journal-title":"Mol. Cell"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13045-018-0605-5","article-title":"The biology and role of CD44 in cancer progression: Therapeutic implications","volume":"11","author":"Chen","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.4161\/cc.6.13.4436","article-title":"Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest","volume":"6","author":"Tarasov","year":"2007","journal-title":"Cell Cycle"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"e001095","DOI":"10.1136\/jitc-2020-001095","article-title":"Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and\/or palliative radiation therapy in patients with advanced solid tumors","volume":"8","author":"Siu","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"758336","DOI":"10.3389\/fonc.2021.758336","article-title":"HIPK3 Inhibition by Exosomal hsa-miR-101-3p Is Related to Metabolic Reprogramming in Colorectal Cancer","volume":"11","author":"Tao","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.21037\/tcr-21-99","article-title":"MicroRNA-221 Promotes Tumor Progression by Targeting HHIP in Human Glioblastoma","volume":"10","author":"Chang","year":"2021","journal-title":"Transl. Cancer Res."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/1724600819843537","article-title":"Clinical Significance of Tumor miR-21, miR-221, miR-143, and miR-106a as Biomarkers in Patients with Osteosarcoma","volume":"2","author":"Zhao","year":"2019","journal-title":"Int. J. Biol. Markers"},{"key":"ref_175","first-page":"1621","article-title":"Overexpression of miR-221 and miR-222 in the Cancer Stroma Is Associated with Malignant Potential in Colorectal Cancer","volume":"40","author":"Iida","year":"2018","journal-title":"Oncol. Rep."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrd.2016.199","article-title":"Aptamers as targeted therapeutics: Current potential and challenges","volume":"16","author":"Zhou","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.2200121","article-title":"Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase","volume":"249","author":"Tuerk","year":"1990","journal-title":"Science"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/S1872-2040(20)60012-3","article-title":"Development of Aptamer Screening against Proteins and Its Applications","volume":"48","author":"Ge","year":"2020","journal-title":"Chin. J. Anal. Chem."},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Ricci, F., Bandello, F., Navarra, P., Staurenghi, G., Stumpp, M., and Zarbin, M. (2020). Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21218242"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1056\/NEJMra0801537","article-title":"Age-related macular degeneration","volume":"358","author":"Jager","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/bjh.15267","article-title":"Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease\/sinusoidal obstruction syndrome","volume":"181","author":"Kernan","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1182\/blood-2015-10-676924","article-title":"Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure","volume":"127","author":"Richardson","year":"2016","journal-title":"Blood"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.3324\/haematol.2018.205930","article-title":"Olaptesed pegol (NOX-A12) with bendamustine and rituximab: A phase IIa study in patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"104","author":"Steurer","year":"2019","journal-title":"Haematologica"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"e002505","DOI":"10.1136\/jitc-2021-002505","article-title":"Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: Modulation of the microenvironment and clinical effects","volume":"9","author":"Williams","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1158\/2326-6066.CIR-16-0303","article-title":"Increasing Tumor-Infiltrating T Cells through Inhibition of CXCL12 with NOX-A12 Synergizes with PD-1 Blockade","volume":"5","author":"Zboralski","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"6923","DOI":"10.1038\/ncomms7923","article-title":"Crystal structure of a mirror-image L-RNA aptamer (Spiegelmer) in complex with the natural L-protein target CCL2","volume":"6","author":"Oberthur","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_187","first-page":"107","article-title":"AS-1411, a guanosine-rich oligonucleotide aptamer targeting nucleolin for the potential treatment of cancer, including acute myeloid leukemia","volume":"12","author":"Mongelard","year":"2010","journal-title":"Curr. Opin. Mol. Ther."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/5\/2736\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:30:19Z","timestamp":1760135419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/5\/2736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":187,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["ijms23052736"],"URL":"https:\/\/doi.org\/10.3390\/ijms23052736","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,1]]}}}